News – Sjogren’s Treatment Report

Signaling Molecule IL-38 Can Reduce Inflammation, May Be Therapy Target, Study Finds

Signaling Molecule IL-38 Can Reduce Inflammation, May Be Therapy Target, Study Finds Signaling Molecule IL-38 Can Reduce Inflammation, May Be Therapy Target, Study Finds

Arginase 1 Protein May Protect from Sjögren’s-related Dryness, Mouse Study Suggests

Arginase 1 Protein May Protect from Sjögren’s-related Dryness, Mouse Study Suggests Arginase 1 Protein May Protect from Sjögren’s-related Dryness, Mouse Study Suggests

Ask the Expert: CBD Oil and Sjögren’s

https://www.sjogrens.org/blog/2020/ask-the-expert-cbd-oil-and-sjogrens Ask the Expert: CBD Oil and Sjögren’s Ask the Expert, Symptoms, Treatment — Aug 12, 2020

OMRF needs participants for Sjögren’s Syndrome study

https://kfor.com/news/local/omrf-needs-participants-for-sjogrens-syndrome-study/ OMRF needs participants for Sjögren’s Syndrome study

University of Queensland and CSL Limited partner up to progress treatments for Sjogren’s syndrome

https://www.uq.edu.au/news/article/2020/07/partnership-progress-treatments-sjogren%E2%80%99s-syndrome Partnership to progress treatments for Sjogren’s syndrome The University of Queensland and global biotechnology company CSL Limited

Luminary Therapeutics, Case Western Team Up to Develop New CAR T-Cell Therapy for Sjogren’s

Luminary Therapeutics, Case Western Team Up to Develop New CAR T-Cell Therapy Luminary Therapeutics, Case Western Team Up to Develop New CAR T-Cell Therapy

Two Projects Using Hydrogel Biomaterials to Stimulate Tissue Regeneration Move Forward with New Funding

https://www.ucsf.edu/news/2020/07/418091/two-projects-using-hydrogel-biomaterials-stimulate-tissue-regeneration-move Two Projects Using Hydrogel Biomaterials to Stimulate Tissue Regeneration Move Forward with New Funding

Luminary Therapeutics and Case Western Reserve University enter formal collaboration for development of BAFF CAR-T (LMY-920) for Sjogren’s Syndrome

https://www.einnews.com/pr_news/521168729/luminary-therapeutics-and-case-western-reserve-university-enter-formal-collaboration-for-development-of-baff-car Luminary Therapeutics and Case Western Reserve University enter formal collaboration for development of BAFF CAR-T (LMY-920) for Sjogren’s Syndrome Luminary Tx and CWRU enter formal collaboration for clinical development of novel BAFF CAR to treat Mantle Cell Lymphoma and Sjogren’s Syndrome MINNEAPOLIS, MN, USA, July 7, 2020 /EINPresswire.com/ — Luminary Therapeutics (Luminary Tx) and […]

Study identifies CP-25 as a potential drug for the treatment of primary Sjögren’s syndrome

New research published in Nature’s Laboratory Investigation shows that CP-25 “increased saliva flow, alleviated the salivary gland indexes, and improved tissue integrity” in a mouse model of primary Sjogren’s syndrome. Researchers “identified the underlying mechanisms of the therapeutic effect of CP-25 and provided an experimental foundation for CP-25 as a potential drug in the treatment […]

How the Hydroxychloroquine (HCQ) Shortage Highlights Sjogren’s Neglect

https://www.sjogrensadvocate.com/post/hcq-i-the-shortage How the hydroxychloroquine (HCQ) shortage highlights Sjogren’s neglect Updated: 4 hours ago

The 2020 Sjögren’s Foundation National Patient Conference (June 26 & June 27, 2020) is going Virtual

https://www.sjogrens.org/news/2020/the-2020-sjogrens-foundation-national-patient-conference-is-going-virtual The 2020 Sjögren’s Foundation National Patient Conference is going Virtual! June 26 & June 27, 2020

Wize Pharma Completes Phase IV Study of LO2A for the Treatment of Dry Eye Syndrome in Patients with Sjögren’s Syndrome

https://www.biospace.com/article/releases/wize-pharma-completes-phase-iv-study-of-lo2a-for-the-treatment-of-dry-eye-syndrome-in-patients-with-sjogren-s-syndrome/ Wize Pharma Completes Phase IV Study of LO2A for the Treatment of Dry Eye Syndrome in Patients with Sjögren’s Syndrome

Targeted Approach for Tackling Sjögren’s Syndrome – Small molecules restore salivary function in mice

https://www.nidcr.nih.gov/news-events/nidcr-news/targeted-approach-tackling-sjogrens-syndrome Targeted Approach for Tackling Sjögren’s Syndrome Small molecules restore salivary function in mice

Abatacept Fails Clinical Trial for Sjögren’s Syndrome

https://www.rheumatologynetwork.com/sjogrens-syndrome/abatacept-fails-clinical-trial-sjgrens-syndrome Abatacept Fails Clinical Trial for Sjögren’s Syndrome

Phase 4 Trial of Treatment for Dry Eyes, LO2A Drops, in Sjögren’s Patients Fully Enrolled

Phase 4 Trial of Treatment for Dry Eyes, LO2A Drops, in Sjögren’s Patients Fully Enrolled Phase 4 Trial of Treatment for Dry Eyes, LO2A Drops, in Sjögren’s Patients Fully Enrolled

Wize Pharma Completes Patient Enrollment In Phase 4 Study Of LO2A for the Treatment of Dry Eye Syndrome in Patients With Sjögren’s Syndrome

https://www.prnewswire.com/news-releases/wize-pharma-completes-patient-enrollment-in-phase-iv-study-of-lo2a-for-the-treatment-of-dry-eye-syndrome-in-patients-with-sjogrens-syndrome-300990264.html Wize Pharma Completes Patient Enrollment In Phase IV Study Of LO2A for the Treatment of Dry Eye Syndrome in Patients With Sjögren’s Syndrome – Topline Results Expected Q2 2020 – Study designed to support approval pathway in the U.S. and other major markets Jan 21, 2020, 09:00 ET HOD HASHARON, Israel, Jan. 21, 2020 […]

Category: News